Exercise in a Pill Is Now in Human Trials - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

  • By

  • Kerri Miller

  • March 18, 2026

  • 2 min

Share

  • 1

    ATR-258 is an oral compound designed to replicate exercise's metabolic effects, including fat loss and muscle preservation.

  • 2

    The compound is a GRK2-biased β2-agonist, selectively activating muscle-building signaling without cardiovascular side effects.

  • 3

    An 8-week human trial at the University of Copenhagen is focused on muscle physiology data in overweight male volunteers.

  • 4

    The study aims to address muscle-sparing weight loss, filling a gap left by current GLP-1 obesity treatments.

  • 5

    Results from the trial are expected later this year, with questions remaining about generalizability and long-term outcomes.

Original Source(s)

Exercise in a Pill Is Now in Human Trials

  • by Kerri Miller

  • March 18, 2026

Related Content

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.

Low Vitamin D Persists Year-Round in Northern Britain

Screening data from a UK clinical trial found low vitamin D levels in 55% of older patients and 72% of ethnic patients, with little variation despite summer months.

Four Patterns in End-of-Life Decline?

International cohort study found physical function declined most rapidly before mortality, while socioeconomic status was associated with more favorable multidomain trajectories.